Overview
A 12-week, randomized, placebo-controlled trial testing the efficacy of n-3 PUFA treatment (EPA, 2 g/day) in alleviating depressive symptoms in a subgroup of obese subjects with comorbid depression and low n-3 PUFA status (n-3 index \< 8%) (81), from the Taiwanese cohort. Associations with PLA2/COX2 genotypes, lifestyle, nutritional profiles and gut microbiota will also be determined.
Eligibility
Inclusion Criteria:
- Major depressive disorder.
- Antidepressant drug-free.
Exclusion Criteria:
- Schizophrenia
- Mania
- Anxiety disorders (except for social phobia and generalized anxiety that are often comorbid with MDD)
- Obsessive-compulsive disorder
- Post-traumatic stress disorder
- Alcohol or drug abuse/dependence (except for nicotine)
- Active suicidal ideation
- Serious medical/neurological conditions, especially requiring corticosteroid/non-steroidal anti-inflammatory or immunosuppressive therapies or chronic thyroid hormone replacement
